期刊
IMMUNOTHERAPY
卷 13, 期 5, 页码 397-407出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2020-0263
关键词
convalescent plasma; SARS-CoV-2; intravenous immunoglobulins; anti-COVID-19 IVIG; passive immunization; pooled plasma; caprylic acid; ultrafiltration; diafiltration; immunotherapy
类别
资金
- Dow University of Health Sciences and Higher Education Commission Pakistan [20-RRG-134/RGM/RD/HEC/2020]
This study successfully produced hyperimmune anti-COVID-19 intravenously administrable immunoglobulin (C-IVIG) with high titers of SARS-CoV-2 antibody using simple technology and locally available pooled convalescent plasma. The safety and efficacy of C-IVIG will be evaluated in a registered clinical trial.
Background: This study assesses the feasibility of producing hyperimmune anti-COVID-19 intravenously administrable immunoglobulin (C-IVIG) from pooled convalescent plasma (PCP) to provide a safe and effective passive immunization treatment option for COVID-19. Materials & methods: PCP was fractionated by modified caprylic acid precipitation followed by ultrafiltration/diafiltration to produce hyperimmune C-IVIG. Results: In C-IVIG, the mean SARS-CoV-2 antibody level was found to be threefold (104 +/- 30 cut-off index) that of the PCP (36 +/- 8.5 cut-off index) and mean protein concentration was found to be 46 +/- 3.7 g/l, comprised of 89.5% immunoglobulins. Conclusion: The current method of producing C-IVIG is feasible as it uses locally available PCP and simpler technology and yields a high titer of SARS-CoV-2 antibody. The safety and efficacy of C-IVIG will be evaluated in a registered clinical trial (NCT 04521309).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据